A potent, cell-permeable, reversible, ATP-competitive, and selective inhibitor of VEGF (Flk-1; IC₅₀ = 1.2 µM) and PDGF (IC₅₀ = 2.9 µM) receptor tyrosine kinases. Does not have any effect on the EGF and IGF receptor tyrosine kinases. Also inhibits the VEGF-driven mitogenesis of human umbilical vein endothelial cells (HUVECs; IC₅₀ ≤ 680 nM). Inhibits Flt3 phosphorylation in Flt3/Itd-BaF3 cells.

Primary Target
VEGF Flk-1

Target IC₅₀: 1.2 µM, 2.9 µM against VEGF (Flk-1) and PDGF receptor tyrosine kinases, respectively; ≤680 nM against the VEGF-driven mitogenesis of human umbilical vein endothelial cells (HUVECs)

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 2 months at -20°C.

Cools, J., et al. 2004. Cancer Res.64, 6385.
Sun, L., et al. 1998. J. Med. Chem. 41, 2588.

Not available for sale in the United States.

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Standard Handling (A)